

Collateral Valuation - Summary

Stock Price Assumptions as of:			
		24-Oct-01	
		Enron	\$16.41
		Compaq	\$9.74
		Eli Lilly	\$78.20

Collateral Valuation Summary					
LTV	BA	Chase	Compass *	FU	Enron
	80.0%	80.0%	80.0%	75.0%	
Original LOC	\$40,000,000	\$15,000,000	\$10,000,000		\$7,500,000
Outstanding	300,000	200,000	789,871	2,063,919	\$5,800,000
Current LTV	8.2%	57.5%	18.4%	65.2%	n/a
Mkt Val Collateral	\$3,676,979	\$347,889	\$4,282,000	\$3,165,941	n/a
Collateral Req.	\$375,000	\$250,000	\$1,625,600	\$2,751,892	n/a
Excess (Deficit)	\$3,301,979	\$97,889	\$414,049		
Borrowing Power	\$2,641,581	\$78,111	\$835,729	\$310,536	\$1,700,000
Total					
					\$9,153,790
					\$5,000,000
					75.0%
					\$6,668,703
					\$6,250,000
					\$418,703
Total all					
					\$8,066,160
Total Available					
					\$418,703
					\$418,703

Allocation of Collateral for Secured LOC				
	BA	Chase	Compass *	FU
Enron	12.0%	44.0%	0.0%	0.0%
Compaq	88.0%	56.0%	0.0%	0.0%
Eli Lilly	0.0%	0.0%	100.0%	0.0%
Cypress	0.0%	0.0%	0.0%	92.6%
Other various	0.0%	0.0%	0.0%	7.4%
	100.0%	100.0%	100.0%	100.0%

* Compass LOC has 80% LTV on all liquid assets held as collateral; the exception is the Sanders' account which consists of illiquid assets that Compass offers the lesser of: 30% LTV or \$1mm

Confidential Treatment
Requested under FOIA

LAY-SEC-1
000000296

LOC 011024
8/8/2002

**Confidential Treatment
Requested under FOIA**

LAY-SEC-1
000000297

LOC: 011024
8/8/2002

	Allocation of Collateral		
	BA	Compass	FU
Enron	18.3%	100.0%	37.2%
Compaq	20.5%	0.0%	0.0%
Eli Lilly	29.5%	0.0%	0.0%
EOAT	1.9%	0.0%	0.0%
TCW	29.8%	0.0%	0.0%
Cypress	0.0%	0.0%	20.3%
Fayez	0.0%	0.0%	42.5%
	100.0%	100.0%	100.0%

<u>PERSONAL</u>	<u>26-Sep</u>	<u>24-Oct</u>	<u>% Chg</u>
Cypress	2,644,016	2,931,191	10.9%

<u>PARTNERSHIP</u>	<u>26-Sep</u>	<u>24-Oct</u>	<u>% Chg</u>
Fayez	869,563	935,804	7.6%
Cypress	406,517	446,304	9.8%
TCW-Select	1,688,881	1,263,177	-25.2%
TCW-Mid	327,879	-	-100.0%
TCW-Small	547,187	335,493	-38.7%

Confidential Treatment
Requested under FOIA

LAY-SEC-1
000000298

Collateral Valuation

Bank of America

Stock Price assumptions		24-Oct-01	
Enron	\$16.41	TCW - Select	\$14.90
Compaq	\$9.74	TCW - Aggr.	\$10.49
Eli Lilly	\$78.20	TCW - Small	\$15.70
EOTT	\$20.05		

\$40,000,000 Partnership Line of Credit to Kenneth L. & Linda P. Leavitt	
Outstanding Loan Balance	\$300,000

Collateral Pledged	Shares	Value	
Enron Corp.	26,862	\$440,805	12.0%
Enron (16.25/sh)	790		
Enron (\$15.81/sh)	9,440		
Enron (\$17.75/sh)	19,920		
Enron (\$14.97/sh)	20,000		
Enron (\$14.97/sh)	20,000		
Enron (\$14.97/sh)	1,551		
Compaq Computer	332,256	\$3,236,173	88.0%
Total Market Value of Collateral		\$3,676,979	100.0%
Less: Collateral Required (80% LTV)	8.16%	\$375,000	

Excess (Deficit) Collateral	\$3,301,979
Borrowing Power	\$2,641,583
Available to Borrow	\$2,641,583

\$40,000,000 Partnership Line of Credit to KLL & LPL Investments Ltd.	
Outstanding Loan Balance	\$4,133,000

Collateral Pledged	Shares	Value	
Compaq (KLL owns)	113,064	\$1,101,243	20.5%
Eli Lilly & Co.	20,220	\$1,581,204	29.5%
EOTT Energy Partners	5,000	\$100,250	1.9%
Enron Corp.	60,000	\$984,600	18.3%
TCW Galileo Select Equities	84,777	\$1,263,177	23.5%
TCW Galileo Aggressive Growth	-	\$0	0.0%
TCW Small Cap Growth	21,369	\$335,493	6.3%
Total Market Value of Collateral		\$5,365,968	100.0%
Less: Collateral Required (LTV 80%)	77.02%	\$5,166,250	

Excess (Deficit) Collateral	\$199,718
-----------------------------	-----------

LOC_011024
8/8/2002

Confidential Treatment
Requested under FOIA

LAY-SEC-1
000000299

Collateral Valuation

Bank of America

Borrowing Power	\$159,774
Available to Borrow	\$159,774

LOC_011024
8/8/2002

Confidential Treatment
Requested under FOIA

LAY-SEC-1
000000300

Collateral Valuation

Chase

24-Oct-01

<u>Stock Price Assumptions</u>	
Enron	\$16.41
Compaq	\$9.74

\$15.0 Million Non Purpose Credit Line

STOCK	Symbol	Certif. No.	Shares	Value	Ownership
Enron Corp (\$11.7)	ENE	Chase Acct	9,329	\$ 153,089	Personal
		Total ENE	9,329	\$ 153,089	44.0%
Compaq	CPQ	BB125523	20,000	\$ 194,800	Personal
		Total CPQ	20,000	\$ 194,800	56.0%
Total Value of Collateral				\$ 347,889	

LTV	80%
AVAILABLE BALANCE	\$278,311
Funded	(\$200,000)
REMAINING BALANCE	\$78,311

LOC_011024
8/8/2002

Confidential Treatment
Requested under FOIA

LAY-SEC-1
000000302

Collateral Valuation

Compass

24-Oct-01

Stock Price Assumption	
Enron	\$16.41
Eli Lilly	\$78.20

\$10.0 Million Non Purpose Credit Line

STOCK	Symbol	Certif. No.	Shares	Ownership	
Eli Lilly	LLY	FC24922	5,000	Personal	
Eli Lilly	LLY	CNY18380	<u>5,000</u>	Personal	
		Total LLY	10,000	782,000	=====
Enron Corp	ENE	HC119322	7,690	Personal	
Enron Corp	ENE	HC119285	22,052	Personal	
Enron Corp	ENE	HC119286	1,751	Personal	
Enron Corp-Split	ENE	HC164652	1,751	Personal	
Enron Corp	ENE	HC119359	4,521	Personal	
Enron Corp-Split	ENE	HC164653	4,521	Personal	
Enron Corp	ENE	HC119360	7,792	Personal	
Enron Corp	ENE	HC127094	<u>9,440</u>	Personal	
		Total ENE		-	0.0%
TOTAL				\$ 782,000	
LTV				80%	
AVAILABLE BALANCE				\$625,600	
Funded				(\$789,871)	
REMAINING BALANCE				(\$164,271)	

Additional Collateral

Sanders Morns Harris (30% LTV, capped at \$1,000,000)

Total	\$ 3,500,000
LTV	30%
AVAILABLE BALANCE	\$ 1,000,000
Funded	\$0
REMAINING BALANCE	\$1,000,000

Summary

Total Collateral	\$ 4,282,000
Available Balance	\$ 1,625,600
Funded	(\$789,871)
Combined Balance (for all Assets)	\$835,729
	18.4%

LOC_011024
8/8/2002

Confidential Treatment
Requested under FOIA

LAY-SEC-1
000000303

Collateral Valuation

Compass

~~Partnership LOC ENRON Corp. & L.P. Investments Ltd.~~

Outstanding Loan Balance

\$520,000

Collateral Pledged	Shares	Value
Enron Corp	25,000	\$410,250
Total Market Value of Collateral		\$410,250
Less: Collateral Required	126.75%	\$650,000

LOC_011024
8/8/2002

Confidential Treatment
Requested under FOIA

LAY-SEC-1
000000304